Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Hypotension 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Catecholamines × Clear all
NCT05451134 2022-07-12

Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

China National Center for Cardiovascular Diseases

Unknown
300 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT03215797 2018-01-23

Phenylephrine or Norepinephrine for a Better Hemodynamic Stability

The Second Affiliated Hospital of Dalian Medical University

Phase 3 Completed
40 enrolled

Hypotension

Data powered by HemOnc (CC BY 4.0) Colophon âš¡